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a b s t r a c t
Primary immunodeﬁciencies (PIDs) are a heterogeneous group of inherited diseases of the immune
system. The deﬁnite diagnosis of PID is ascertained by genetic analysis; however, this takes time and is
costly. Flow cytometry provides a rapid and highly sensitive tool for diagnosis of PIDs.
Flow cytometry can evaluate speciﬁc cell populations and subpopulations, cell surface, intracellular
and intranuclear proteins, biologic effects associated with speciﬁc immune defects, and certain func-
tional immune characteristics, each being useful for the diagnosis and evaluation of PIDs. Flow cytometry
effectively identiﬁes major forms of PIDs, including severe combined immunodeﬁciency, X-linked
agammaglobulinemia, hyper IgM syndromes, Wiskott-Aldrich syndrome, X-linked lymphoproliferative
syndrome, familial hemophagocytic lymphohistiocytosis, autoimmune lymphoproliferative syndrome,
IPEX syndrome, CTLA 4 haploinsufﬁciency and LRBA deﬁciency, IRAK4 and MyD88 deﬁciencies, Men-
delian susceptibility to mycobacterial disease, chronic mucocuneous candidiasis, and chronic granulo-
matous disease. While genetic analysis is the deﬁnitive approach to establish speciﬁc diagnoses of PIDs,
ﬂow cytometry provides a tool to effectively evaluate patients with PIDs at relatively low cost.
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8; FHL, familial hemophagocytic
lymphohistiocytosis; FOXP3, forkhead box
P3; HIES, hyper IgE syndrome; HIGM, hyper
IgM syndrome; ICOS, inducible
co-stimulator; IFN, interferon;
iNKT, invariant natural killer T;
IPEX, immune dysregulation,
polyendocrinopathy, enteropathy, X-linked
inheritance syndrome; IRAK4, IL-1 receptor-
associated kinase 4; JAK3, Janus kinase 3;
LAD, leukocyte adhesion deﬁciency;
LPS, lipopolysaccharide;
LRBA, lipopolysaccharide-responsive and
beige-like anchor protein; mAb, monoclonal
antibody; MSMD, Mendelian susceptibility
to mycobacterial disease; MyD88, myeloid
differentiation primary response gene 88;
NOD, nucleotide-binding and
oligomerization domain; PBMCs, peripheral
blood mononuclear cells; PIDs, primary
immunodeﬁciency diseases; PNP, purine
nucleoside phosphorylase;
RAG, recombination activating gene;
SAP, SLAM-associated protein; SCID, severe
combined immunodeﬁciency; STAT, signal
transducer and activator of transcription;
TCR, T-cell receptor; Th, T helper; TLR, Toll-
like receptor; TNF, tumor necrosis factor;
WAS, Wiskott-Aldrich syndrome;
WASp, WAS protein; XIAP, X-linked
inhibitor of apoptosis; XLA, X-linked
agammaglobulinemia; XLP, X-linked
lymphoproliferative syndrome; XLT, X-
linked thrombocytopenia; X-SCID, X-linked
severe combined immunodeﬁciency;
ZAP70, z-chain-associated protein kinase of
70 kDa
Introduction
Primary immunodeﬁciency diseases (PIDs) are a heterogenous
group of monogenetic disorders of the immune system, resulting in
recurrent and/or severe infections, autoimmunity, auto-
inﬂammation, or malignancies. A careful history focused on the
types of infectious agents and other complications are important
clues to suspect PID. Laboratory investigations including complete
blood count, immunoglobulin levels, antibody titers, assessment of
neutrophil function and complement components are also impor-
tant tools to conﬁrm the diagnosis of PID. As the spectrum of PIDs is
expanding, it is often difﬁcult to diagnose PIDs based on clinical and
conventional laboratory ﬁndings alone. The more recently available
genetic investigation is a deﬁnitive tool for diagnosing PIDs; how-
ever, DNA analysis takes time and is expensive. In contrast, tech-
nologies that use physical and chemical characteristics of
ﬂuorescent-labeled particles in ﬂuid phase passed through lasers
are cheeper than gene analysis, although they need experienced
and skilled investigators. Thus, ﬂow cytometry may serve as a
bridge between conventional immunological testing and DNA
sequencing, offering rapid and accurate results based on single cell
analysis.1
Application of ﬂow cytometry in the diagnosis of primary
immunodeﬁciency diseases
Flow cytometry is a highly sensitive tool for evaluating the im-
mune system and supporting the diagnosis of PID. The applications
of ﬂow cytometry in the evaluation of PIDs are multiplex and
include the investigation of speciﬁc cell populations and sub-
populations, speciﬁc cell membrane, intracellular and intranuclear
proteins, biologic effects associated with immune defects, and
functional immune abnormalities (Table 1).2
Quantitative assessment of cell populations and subpopulations
is useful for the diagnosis of X-linked agammaglobulinemia (XLA)
characterized by the absence of B cells in the peripheral blood.
Patients with severe combined immunodeﬁciency (SCID) lack T
cells, while the impact on B and NK cells is variable depending on
the genetic defect. Patients with X-linked lymphoproliferative
syndrome type 1 (XLP1) have a marked decrease in invariant nat-
ural killer T (iNKT) cells. Autoimmune lymphoproliferative syn-
drome (ALPS) is characterized by increased T-cell receptor (TCR)-a/
b-positive double-negative T (DNT) cells. Patients with autosomal
dominant hyper IgE syndrome (HIES), and those with chronic
mucocutaneous candidiasis (CMCD) present with decreased num-
ber of circulating T helper (Th)17 cells.
As speciﬁc cell surface proteins are concerned, unique subsets of
patients with common variable immunodeﬁciency (CVID) can be
characterized by assessing CD19þ B cells, B-cell activating factor
receptor (BAFF-R) on B cells, and the inducible co-stimulator (ICOS)
on activated T cells. Patients with X-linked hyper IgM syndrome (X-
HIGM) fail to express CD40 ligand (CD40L) on activated T cells, and
a group of patients with autosomal recessive hyper IgM syndrome
lack CD40 expression on B cells. Mendelian susceptibility to
mycobacterial disease (MSMD) has been associated with aberrant
interferon (IFN)-gR1 expression on monocytes or deﬁcient IL-
12Rb1 expression on activated T cells. Patients with leukocyte
adhesion deﬁciency type 1 (LAD1) can be identiﬁed by absent
expression of CD18 on granulocytes. Lymphocytes from patients
with X-linked SCID (X-SCID) show deﬁcient CD132 (common g
chain) expression. Patients suffering from gp91-phox- and p22-
phox-deﬁcient chronic granulomatous disease (CGD), lacking the
H. Kanegane et al. / Allergology International 67 (2018) 43e5444
membrane bound cytochrome b558, can be identiﬁed using
monoclonal antibody (mAb) 7D5 against cytochrome b558
expressed by granulocytes and B cells. Lack of IL-17RA expression
on lymphocytes and monocytes is typical for patients with chronic
mucocutaneous candida infection and IL-17RA deﬁciency.
A large number of PIDs can be diagnosed by analyzing expres-
sion of speciﬁc intracellular proteins. Patients with XLA generally
lack Bruton's tyrosine kinase (BTK) expression in monocytes and
platelets. Patients suffering from the Wiskott-Aldrich syndrome
(WAS) or X-linked thrombocytopenia (XLT) showabsent or reduced
expression of WAS protein (WASp) in lymphocytes and myeloid
cells. Patients with XLP1 lack expression of SLAM-associated pro-
tein (SAP) in lymphocytes. Lymphocytes from patients with XLP2
lack expression of X-linked inhibitor of apoptosis (XIAP) protein.
Patients experiencing familial hemophagocytic lymphohistiocy-
tosis type 2 (FHL2) can be identiﬁed by absent perforin expression
in CD8þ T cells and NK cells. Patients with FHL3 demonstrate
reduced expression of Munc13-4 in platelets. Patients with z-chain-
associated protein kinase of 70 kDa (ZAP70) deﬁciency lack
expression of ZAP70 in lymphocytes. Neutrophils from patients
with X-linked CGD lack gp91-phox, and those from patients with
autosomal recessive CGD due to p47-phox and p67-phox mutation
lack relevant protein expression. Most patients with dedicator of
cytokinesis 8 (DOCK8) deﬁciency lack expression of DOCK8 in
lymphocytes. Both cytotoxic T-lymphocyte-associated protein 4
(CTLA4) haploinsufﬁciency and lipopolysaccharide-responsive and
beige-like anchor protein (LRBA) deﬁciency have in common low
CTLA4 expression in CD4þFOXP3þ regulatory T cells. Most patients
Table 1
Application of ﬂow cytometry in the diagnosis of primary immunodeﬁciency diseases.
Disease Test
Evaluate for speciﬁc cell population and subpopulation
XLA Absent B cells
SCID Absent T cells and variable number of B and NK cells (depending on defect)
XLP1 Markedly reduced iNKT cells
ALPS Increased TCR-a/bþ double-negative (CD4eCD8e) T cells
HIES and CMCD Decreased Th17 cells
Evaluate of speciﬁc cell surface protein
CVID CD19 on B cells
BAFF-R on B cells
ICOS on activated T cells
X-linked HIGM CD40L on activated T cells
Autosomal recessive HIGM CD40 on B cells
MSMD IFN-gR1 on monocytes
IL-12Rb1 on activated T cells
LAD1 CD18 on granulocytes
X-SCID CD132 on lymphocytes
gp91-phox and p22-phox deﬁcient CGD Cytochrome b558 on granulocytes and B cells
IL-17RA deﬁciency IL-17RA on lymphocytes and monocytes
Evaluate of speciﬁc intracellular protein
XLA BTK in monocytes and platelets
Wiskott-Aldrich syndrome and X-linked thrombocytopenia WASp in lymphocytes and myeloid cells
XLP1 SAP in CD8þ T cells and NK cells
XLP2 XIAP in lymphocytes
FHL2 Perforin in CD8þ T cells and NK cells
FHL3 Munc13-4 in platelets
ZAP70 deﬁciency ZAP70 in T cells
p47-phox and p67-phox deﬁcient CGD p47-phox and p67-phox protein in granulocytes
DOCK8 deﬁciency DOCK8 in lymphocytes
CTLA4 haploinsufﬁciency and LRBA deﬁciency CTLA4 in CD4þFOXP3þ T cells
Evaluate of speciﬁc nuclear protein
IPEX FOXP3 in CD4þCD25þ T cells
Evaluate biologic effects
CVID Decreased switched memory B cells
Omenn syndrome and hypomorphic SCID Oligoclonal TCR/diversity
X-linked HIGM Decreased memory B cells and memory CD4þ T cells
Evaluate function
MSMD STAT1 phosphorylation in monocytes in response to IFN-g
CMCD (STAT1 gain-of-function) STAT1 phosphorylation in monocytes in response to IFN-g
FHL3/4/5, Chediak-Higashi syndrome and Griscelli syndrome CD107a expression in NK cells and CTLs
XLP2 TNF-a in monocytes in response to muramyl dipeptides
CGD DHR123 assay in granulocytes, monocytes and B cells
X-SCID and JAK3-deﬁcient SCID STAT phosphorylation in lymphocytes in response to cytokine stimulation
X-linked HIGM No binding of CD40L and CD40-Ig
IRAK4 and MyD88 deﬁciency TNF-a in monocytes in response to LPS
IL-10R deﬁciency STAT3 phosphorylation in lymphocytes in response to IL-10
Infantile-onset multisystem autoimmune disease 1
(heterozygous GOF mutation in STAT 3)
Increased STAT3 phosphorylation
XLA, X-linked agammaglobulinemia; SCID, severe combined immunodeﬁciency; XLP, X-linked lymphoproliferative syndrome; iNKT, invariant natural killer T; ALPS, auto-
immune lymphoproliferative syndrome; TCR, T-cell receptor; HIES, hyper IgE syndrome; CMCD, chronic mucocutaneous candidiasis disease; CVID, common variable im-
munodeﬁciency; BAFF-R, B-cell activating factor receptor; ICOS, inducible co-stimulator; HIGM, hyper IgM syndrome; CD40L, CD40 ligand; MSMD, Mendelian susceptibility to
mycobacterial disease; IFN, interferon; IL, interleukin; LAD, leukocyte adhesion deﬁciency; CGD, chronic granulomatous disease; BTK, Bruton tyrosine kinase; WASp, Wiskott-
Aldrich syndrome protein; SAP, signaling activation molecule-associated protein; XIAP, X-linked inhibitor of apoptosis; FHL, familial hemophagocytic lymphohistiocytosis;
FOXP3, forkhead box P3; ZAP70, z-chain -associated protein kinase of 70 kDa; DOCK8, dedicator of cytokinesis 8; CTLA4, cytotoxic T-lymphocyte-associated protein 4; LRBA, LPS
responsive beige-like anchor protein; IPEX, immune dysregulation, polyendocrinopathy, enteropathy, X-linked; STAT, signal transducer and activator of transcription; CTLs,
cytotoxic T lymphocytes; DHR, dehydrorhodamine; JAK3, Janus kinase 3; IRAK4, interleukin-1 receptor-associated kinase 4; MyD88, myeloid differentiation primary response
gene 88; TNF, tumor necrosis factor; LPS, lypopolysaccharide; GOF, gain-of-function. This table is modiﬁed from Reference2 with permission.
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Fig. 1. Flow cytometry in a patient with X-linked severe combined immunodeﬁciency. A, Patient T cells (CD3þ), B cells (CD19þ), and NK cells (CD16þCD56þ) were separated based on
the lymphocyte gate. T and NK cells are absent, and the number of B cells are increased. B, CD132 (common g chain) expression by CD19þ B cells. Patient cells lack CD132 expression.
Gray shaded area, isotype control; black line, anti-CD132 staining. C, Flow cytometric evaluation of STAT5 phosphorylation following IL-2 stimulation. Patient cells fail to respond.
Gray shaded area, no stimulant; black line, 20 min post-IL-2 stimulation. D, Flow cytometric evaluation of STAT3 phosphorylation following IL-21 stimulation. Patient cells fail to
respond. Gray shaded area, no stimulant; black line, 20 min post-IL-21 stimulation.
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presenting with immune dysregulation, polyendocrinopathy, en-
teropathy, X-linked inheritance syndrome (IPEX) have low or ab-
sent nuclear forkhead box P3 (FOXP3) expression by CD4þCD25þ
regulatory T cells.
Flow cytometry techniques are now available to evaluate bio-
logic effects of mutated genes, and the results can be used for the
diagnosis of relevant PIDs. Most patients with CVID or hyper IgM
syndromes have decreased switched memory B cells. Omenn syn-
drome and most hypomorphic SCID syndromes are characterized
by an oligoclonal T-cell repertoire.
The introduction of functional tests using ﬂow cytometry has
provided a powerful tool to evaluate important pathways of
cognate and innate immunity. Patients with MSMD due to muta-
tions in genes of the IL12/23-IFNg pathway can be identiﬁed by
demonstrating reduced phosphorylation of signal transducer and
activator of transcription (STAT)1 expression in response to stim-
ulation with cytokines. Peripheral blood mononuclear cells
(PBMCs) from patients with CMCD respond with reduced phos-
phorylation of STAT1 when stimulated with IFN-g. Patients with
FHL3/4/5, Chediak-Higashi and Gricelli syndrome demonstrate
reduced CD107a expression in resting NK cells and in cytotoxic T
lymphocytes (CTLs). Monocytes of patients with XLP2 respondwith
reduced tumor necrosis factor (TNF)-a production by monocytes in
response to muramyl dipeptide. CGD patients regardless of the
molecular defect show reduced or absent dihydrorhodamine (DHR)
123 reduction in granulocytes, monocytes and B cells. Patients with
X-SCID and Janus kinase 3 (JAK3)-deﬁcient SCID demonstrate
reduced phosphorylation of STAT3 and STAT5 in response to
cytokine-stimulation. IL-1 receptor-associated kinase 4 (IRAK4) and
myeloid differentiation primary response gene 88 (MyD88) de-
ﬁciencies can be identiﬁed by reduced TNF-a production in
monocytes in response to lipopolysaccharide (LPS). Patients with
IL-10 receptor deﬁciency demonstrate reduced STAT3 phosphory-
lation when stimulated with IL-10. Infantile-onset multisystem
autoimmune disease 1, caused by heterozygous gain-of-function
mutation in STAT3, is typically associated with increased STAT3
phosphorylation by unstimulated lymphocytes.
The following are examples illustrating the application of ﬂow
cytometry for the diagnosis of molecularly deﬁned PIDs.
Severe combined immunodeﬁciency
SCID disorders, the most severe forms of PID, are generally
characterized by complete absence of T-cell mediated immunity































































Fig. 2. Flow cytometry in a patient with X-linked agammaglobulinemia (XLA). A, CD19þCD20þ B cells are markedly reduced. B, Bruton's tyrosine kinase (BTK) expression is absent in
patient monocytes. A bimodal or mosaic pattern of BTK expression is demonstrated in the heterozygous carrier. Gray shaded area, isotype control; black line, anti-BTK monoclonal
antibody.
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by immunophenotypic characteristics based on ﬂow cytometry.
TBNK SCID includes reticular dysgenesis and adenosine
deaminase (ADA) deﬁciency. TBNKþ SCID suggest mutations
affecting the recombination activating genes (RAG)1 and RAG2,
Artemis, DNA ligase IV, and Cernunnos. TBþNK phenotype is
characteristic for X-SCID and JAK3 deﬁciency. TBþNKþ SCID in-
cludes IL-7Ra, CD3d, CD3ε and CD3z deﬁciencies. In X-SCID, rep-
resenting close to half of all SCID patients,4 T and NK cells are absent
while B cell counts are normal or high (Fig. 1A). The gene respon-
sible for X-SCID is IL2RG, coding for the common g chain (CD132).
Therefore, the absence of CD132 by ﬂow cytometry strongly sug-
gests X-SCID (Fig. 1B), although a few patients with mutations in
the cytoplasmic domain of the IL2RG may express normal CD132.
Since the common g chain is also part of the IL-4, IL-7, IL-9, IL-15,
and IL-21 receptors, these cytokines constitute the speciﬁc ligands
for all pathways that depend on a functional common g chain.
Phosphorylation of intracellular STATs can be evaluated by ﬂow
cytometry using mAbs that recognize only STATs that are phos-
phorylated. As shown in Figure 1C,D, patients with X-SCID have
impaired tyrosine phosphorylation of STAT5 and STAT3 in response
to stimulation with IL-2 and IL-21, respectively. This assay also
identiﬁes JAK3 deﬁciency because JAK3 interacts intracellularly
with the common g chain. ZAP70 deﬁciency is a form of SCID
characterized by CD8 deﬁciency; patients with ZAP70 deﬁciency
lack expression of ZAP70 in T cells.5
X-linked agammaglobulinemia
XLA is characterized by the absence of circulating B cells and
severe reduction of all serum immunoglobulins due tomutations in
the BTK gene. Absent or markedly reduced B cell numbers, deter-
mined by ﬂow cytometry based on the lack of CD19- and/or CD20-
expressing cells, are typical for all forms of agammaglobulinemia
(Fig. 2A). Therefore, assessment of BTK is mandatory for the diag-
nosis of XLA.6 Because patients with XLA have no B cells, intracel-
lular BTK expression has to be evaluated in monocytes or platelets
(Fig. 2B).7,8 This technique can also be used for the detection of XLA
carriers. Absent of reduced expression of BTK strongly suggests
XLA, but normal quantity of BTK does not rule out the diagnosis, as
some patients with XLA express normal amount of nonfunctional
BTK protein.9 B cell-deﬁcient patients with wild type BTKmay have
autosomal recessive agammaglobulinemia, and sequence analysis
of m heavy chain, Iga, Igb, l5, BLNK, E47 or PI3KR1 is required.
Hyper IgM syndromes
HIGM syndromes are a group of genetic disorders affecting







































































Fig. 3. Flow cytometric identiﬁcation of CD154 (CD40L) on activated T cells in a patient with X-linked hyper IgM syndrome. A, Peripheral blood mononuclear cells were cultured
with phorbol myristate acetate and ionomycin for 3.5 h. The cells are CD69-positive, indicating activated T cells, but only control CD69-positive cells express CD152. B, CD154
expression on CD3þCD8 T cells was evaluated. The patient's cells failed to express CD154. Gray shaded area, isotype control; black line, anti-CD154 monoclonal antibody.
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somatic hypermutation.10 Affected patients present with normal or
increased serum IgM, and low levels of IgG and IgA. While muta-
tions in several genes have been associated with HIGM, the most
frequently affected gene is CD40L with X-linked recessive inheri-
tance. CD40L-deﬁcient patients develop not only bacterial but also
opportunistic infections and malignancies, implying the important
role of CD40L in T cell function. CD40L (CD154) expression by
activated CD4þ T cells is absent or reduced when assessed by anti-
CD40L speciﬁc mAbs in most but not all patients with X-linked
HIGM (Fig. 3), since some mutations result in non-functional pro-
tein that nevertheless can bind to epitope neutral mAbs.11 In
contrast, only functional CD40L can bind to the CD40-Ig construct,
providing a ﬂow cytometry-based functional assay for X-linked
HIGM.12 CD40 deﬁciency, one of several autosomal recessive HIGM
syndromes, is a phenocopy of CD40L deﬁciency that can be iden-
tiﬁed by assessing CD40 expression on B cells, monocytes, or den-
dritic cells.13 Except for CD40L and CD40 deﬁciency, none of the
other HIGM syndrome can be identiﬁed by ﬂow cytometry.
Common variable immunodeﬁciency
CVID is a heterogenous group of disorders characterized by
hypogammaglobulinemia, defective speciﬁc antibody production
and increased susceptibility to recurrent and chronic infections,
and often to autoimmunity, lymphoproliferative disorders and
cancer.14 Patients with CVID have normal or low numbers of B cells.
B cells can be subdivided into naïve (CD27IgDþIgMþ), IgM mem-
ory (CD27þIgDþIgMþ), and switched memory (CD27þIgDIgM) B
cells based on CD27 and IgD/IgM expression.15 Most patients with
CVID show a decreased number of switched memory B cells.
Decreased numbers of switched memory B cells are also observed
in HIGM syndromes.16
A small subset of CVID are caused bymutations in ICOS,CD19, and
BAFFR (TNFRSF13C). These patients can be screened by ﬂow cytom-
etry. Patients with ICOS deﬁciency were reported to have reduced
up-regulation of ICOS by activated T cells.17 BAFFR is constitutively
expressed on B cells, and patients with BAFFR mutations show
reduced expression of this protein.18 CD19 forms complexes with
CD21, CD81, and CD225 which collaborate with the B cell receptor
upon antigen recognition. Absence of CD19 expression on B cells has
been observed in patients with CD19 and CD81 deﬁciencies.19e21
Wiskott-Aldrich syndrome and X-linked thrombocytopenia
WAS is a rare X-linked disorder characterized by persistent
microthrombocytopenia, eczema, cellular and humoral immuno-
deﬁciency, and an increased risk of autoimmune disease and he-
matologic malignancy.22 WAS is caused by mutations in the WAS
gene encoding the WASp; this gene is also responsible for XLT and
X-linked neutropenia. Monoclonal antibodies against WASp are
useful for screening patients suspected to have WAS or XLT
(Fig. 4).23,24 This technique is also of value in the evaluation of
chimerism after hematopoietic stem cell transplantation and so-
matic reversion mosaicism of the WAS gene.25,26
X-linked lymphoproliferative syndrome
XLP, a rare PID with susceptibility to EpsteineBarr virus infec-
tion, is clinically characterized by hemophagocytic lymphohistio-
cytosis and hypogammaglobulinemia, with or without lymphoma.
XLP is classiﬁed into type 1 (XLP1) caused by mutations in the
SH2D1A gene encoding SAP and type 2 (XLP2) caused by mutations
in the XIAP or BIRC4 gene encoding XIAP. Flow cytometric detection
of intracellular SAP and XIAP proteins are useful screening tests for
the identiﬁcation of patients with XLP1 and XLP2, respectively
Control
PaƟent
CD3+ T cells CD19+ B cells CD14+ monocytes
WASp
Fig. 4. Flow cytometric detection of WASp in a patient with Wiskott-Aldrich syndrome. Cytoplasmic WASp expression was markedly reduced in patient CD3þ T cells, CD19þ B cells,
and CD14þ monocytes. Gray shaded area, isotype control; black line, anti-WASp mAb.
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Fig. 5. Flow cytometry in patients with X-linked lymphoproliferative syndrome type 1 (XLP1) and XLP2. A, SAP expression was markedly reduced in CD8þ T cells and CD56þ NK
cells from a patient with XLP1. B, XIAP expression was reduced in lymphocytes and monocytes from a patient with XLP2. Gray shaded area, isotype control; black line, anti-SAP or
anti-XIAP monoclonal antibody.
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(Fig. 5A,B).27,28 While patients with XLP1 have extremely reduced
numbers of iNKT cells, patients with XLP2 have variable low
numbers of iNKT cells. Flow cytometry is also useful to identify
atypical cases of XLP including somatic reversion mosaicism of
XLP1, and female XLP2.29,30 Because XIAP plays an essential role in
nucleotide-binding oligomerization domain protein (NOD)1/2
signaling, ﬂow cytometric assessment of TNF-a production by
monocytes in response to NOD2 stimulation by muramyl dipeptide
is a useful functional approach for diagnosing XIAP deﬁciency. TNF-
a production was found to be severely diminished in all patients
with XIAP deﬁciency studied.31
Familial hemophagocytic lymphohistiocytosis
FHL is a group of genetically determined, life-threatening dis-
orders associated with the uncontrolled proliferation of activated
lymphocytes and histiocytes secreting large amounts of inﬂam-
matory cytokines.32 Genetic defects affecting granule-mediated
cytotoxicity are associated with FHL, including perforin (FHL2),
Munc13-4 (FHL3), syntaxin 11 (FHL4), and Munc 18-2 (FHL5) de-
ﬁciencies. FHL2 can be evaluated by assessing perforin expression
in CD56þCD16þ NK cells and CD8þ T cells (Fig. 6A),33 and FHL3 can
be screened by detecting Munc13-4 expression in platelets
(Fig. 6B).34 Assessment of the release of cytolytic granules by
measuring surface expression of CD107a by NKor cytotoxic Tcells is
useful for the diagnosis of FHL3.35,36 This assay has also been sug-
gested for the diagnosis of FHL 4, FHL5, Chediak-Higashi syndrome
and Griscelli syndrome, all having in common defects in granule-
mediated cytotoxic pathways.37
Autoimmune lymphoproliferative syndrome
ALPS is a disorder of lymphocyte homeostasis characterized by
chronic non-malignant lymphoproliferation, autoimmune manifes-
tations (mainly autoimmune cytopenia) and an increased incidence
of lymphoid malignancies.38 Most patients with ALPS harbor muta-
tions in genes which regulate the extrinsic Fas-mediated pro-
grammed cell death pathway (FAS, FASLG and CASP10). An
immunological hallmark of this syndrome is the increased level of
circulating TCR-a/bþCD4CD8 T cells, referred to as DNT cells
(Supplementary Fig. 1A). While control T cells undergo robust
apoptosis as shownbyannexinV-positive cells following stimulation
with anti-FAS antibody, ALPS patient T cells do not (Supplementary
Fig. 1B).
IPEX syndrome
IPEX syndrome, a rare X-linked autoimmune disorder caused by
mutations in the FOXP3 gene, is characterized by severe enteropa-
thy, endocrinopathies (diabetes and/or thyroiditis), and eczematous



















































Fig. 6. Flow cytometric detection of patients with FHL2 and FHL3. A, Reduced perforin expression in NK cells (CD3CD56þCD16þ lymphocyte population) from a FHL2 patient. Solid
histograms represents staining with isotype control antibody and open histograms represent staining with anti-perforin antibody. B, Reduced Munc13-4 expression in platelets
(CD41aþ population) from a FHL3 patient. Solid histograms represent stainingwith control rabbit serum and open histograms represents stainingwith anti-Munc13-4 rabbit antibody.
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and function of CD4þCD25þ regulatory T (Treg) cells. Most IPEX
patients lack or have reduced numbers of CD4þCD25þFOXP3þ or
CD4þCD25þCD127low Treg cells. Interestingly, a sufﬁcient number
of CD4þCD25þCD127low cells were observed in patients with
hypomorphic FOXP3mutations.40 Because CD25 (a chain of the IL-2
receptor) and STAT5b affect Treg development and function, pa-
tients with CD25 or STAT5b mutations present with an IPEX-like
phenotype.41,42 Although reduced in number, Treg cells from
these patients express FOXP3.
CTLA4 haploinsufﬁciency and LRBA deﬁciency
CTLA4 is a costimulatorymolecule expressed by activated Tcells,
and, similar to the T-cell costimulatory molecule CD28, binds to B7-
1 (CD80) and B7-2 (CD86) on the surface of antigen-presenting
cells. CTLA4 transmits an inhibitory signal to T cells, whereas
CD28 transmits a stimulatory signal. Heterozygous loss-of-function
mutations in the CTLA4 gene have been identiﬁed in CVID patients
with IPEX-like phenotype including enteropathy and autoimmune
cytopenias.43,44 Patients with CTLA4 haploinsufﬁciency show
reduced expression of CTLA4 in activated CD4þFOXP3þ T cells
(Supplementary Fig. 2). Biallelic loss-of-function mutations in LRBA
were identiﬁed in patients with the clinical diagnosis of CVID with
ALPS- or IPEX-like manifestations.45,46 A common denominator is
early onset of severe autoimmunity, often associatedwith recurrent
infections and lymphoproliferative disease with increased risk of
lymphoma. Because LRBA colocalizes with CTLA4 in endosomal
vesicles, LRBA deﬁciency increases CTLA4 turnover, resulting in
reduced levels of CTLA4 protein in FOXP3þ regulatory and activated
conventional T cells.47 The phenotypic similarity between LRBA and
CTLA4 deﬁciencies may be explained by this common defect in
CTLA4 expression.
IRAK4 and MyD88 deﬁciency
IRAK4 is a kinase that plays a crucial role in Toll-like receptor
(TLR) and IL-1 receptor signaling. Ligand binding to these receptors
triggers the recruitment of the adaptor proteins MyD88, IRAK4, and
IRAK1, resulting in downstream signal transduction. Autosomal
recessive IRAK4 and MyD88 deﬁciency impair TLR and IL-1 recep-
tor-mediated immunity, resulting in invasive bacterial, especially
pneumococcal infections.48 Intracellular TNF-a production in
monocytes in response to LPS (a TLR4 ligand) was assayed by ﬂow
cytometry and found to be diminished in patients with IRAK4
deﬁciency (Supplementary Fig. 3).49 This assay may also be useful
for the screening of patients with MyD88 deﬁciency.
Fig. 7. Flow cytometric analysis of dihydrorhodamine (DHR) oxidation and expression of p47phox, p67phox and gp91phox in CGD patients and a carrier mother. In the DHR assay,
granulocytes were analyzed using DHR123 as a ﬂuorescent probe before (solid histogram) and after (open histogram) stimulation with phorbol myristate acetate (ﬁrst column of
panels). Expression of gp91phox in patient granulocytes, as assessed using 7D5 (second column of panels). Expression of p47phox and p67phox in CD14þ monocytes are shown in
third and fourth column. Solid histograms indicate isotype control antibody and open histograms represent anti-subunit monoclonal antibodies.
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Mendelian susceptibility to mycobacterial disease
MSMD represents a group of PIDs characterized by vulnerability
to infection with weakly virulent mycobacteria and Salmonella.50
Affected patients may have mutations in genes involved in the IL-
12/23-IFN-g pathway. Patients with IL-12Rb1 and IFNgR1 de-
ﬁciencies can be screened by ﬂow cytometry. Most patients with IL-
12Rb1 and autosomal recessive IFNgR1 deﬁciencies demonstrate
absence of cell surface protein. In contrast, IFNgR1 expression was
increased in a patient with autosomal dominant form of IFNgR1
deﬁciency due to overexpression of the abnormal IFNgR1 chain
(Supplementary Fig. 4).
Chronic mucocutaneous candidiasis
CMCD is characterized by persistent or recurrent C. albicans
infections of skin, nail, andmucosal membranes.51 CMCD refers to a
hetergenous group of PIDs including autosomal dominant HIES
associated with heterozygous STAT3mutation, IL-12p40 deﬁciency,
IL-12Rb1 deﬁciency, and autoimmune polyendocrinopathy-candi-
diasiseectodermal dystrophy/dysplasia (APECED). Patients with
CMCD often have decreased levels of Th17 cells, as do patients with
HIES.52 Those with APECED may develop neutralizing autoanti-
bodies against IL-17A, IL-17F, and/or IL-22, explaining the devel-
opment of CMCD. Of the recently discovered autosomal recessive
IL-17RA and autosomal dominant IL-17F deﬁciencies associated
with CMCD,53 IL-17RA deﬁciency can be readily diagnosed by the
absence of IL-17RA on the surface of circulating lymphocytes and
monocytes.54 The most common cause of CMCD are heterozygous
gain-of-function mutations in STAT1.55,56 Flow analysis readily
recognizes elevated levels of phosphorylated STAT1 that persist
following IFN-g stimulation of monocytes from patients with STAT1
gain-of-function mutations (Supplementary Fig. 5).57 In contrast to
control cells, the tyrosine kinase inhibitor, staurosporine, did not
reduce STAT1 phosphorylation in monocytes obtained from pa-
tients with STAT1 gain-of-function mutations.
Chronic granulomatous disease
CGD is a genetically heterogeneous PID affecting bactericidal
function of phagocytes and characterized by recurrent bacterial and
fungal infections. CGD is caused by defects in the NADPH oxidase
complex, which is responsible for the phagocyte respiratory burst
leading to the generation of superoxide and other reactive oxygen
species. Mutations in ﬁve components (gp91phox, p22phox, p47phox,
p67phox, and p40phox) of the NADPH complex account for the X-
linked and autosomal recessive forms of CGD. Laboratory diagnosis
of CGD is performed by the measurement of superoxide produc-
tion, and is evaluated by ﬂow cytometry using DHR123 oxidation
(Fig. 7). This method allows the distinction between X-linked and
autosomal recessive CGD, and detection of carriers of X-linked
CGD.58 Subtypes of CGD can be determined by genetic as well as
ﬂow cytometric analysis. The 7D5 mAb recognizes the surface
components of NADPH oxidase, and patients with gp91phox and
p22phox deﬁciencies can be diagnosed using this antibody (Fig. 7).59
Patients with p47phox and p67phox deﬁciencies can be identiﬁed
with intracellular staining using anti-p47phox and p67phox speciﬁc
monoclonal antibodies, respectively.60
All the staining protocols are available in Supplementary
Methods.
Conclusion
Flow cytometry is an instrumental tool for the evaluation and
diagnosis of PIDs. The use of ﬂow cytometry provides rapid results
and often suggests the correct diagnosis. While genetic analysis
delivers a deﬁnitive diagnosis, ﬂow cytometry plays an important
role in the cost-effective evaluationof patients suspected tohavePID.
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